VKORC1 polymorphisms explain 30% of the dose variation between patients:[REF] particular mutations make VKORC1 less susceptible to suppression by warfarin [REF].
Despite the promise of pharmacogenomic testing in warfarin dosing, its use in clinical practice is controversial.